Upper-extremity approach for secondary access safer for patients undergoing transfemoral TAVI: JAMA

A new study published in the Journal of American Medical Association showed that the upper-extremity route for secondary access was linked to reduced clinically significant access site-related bleeding in patients receiving transfemoral transcatheter aortic valve implantation (TAVI) when compared to the traditional lower-extremity technique.

During transfemoral transcatheter aortic valve implantation, an upper-extremity secondary access technique may lessen hemorrhage associated with clinically significant secondary access sites. In order to examine the safety and effectiveness of an upper-extremity approach vs a lower-extremity approach in patients having TAVI, this study by Bohdan Nosyk and team was carried out.

This randomized clinical trial ran from November 28, 2022 to November 15, 2023, with a 30-day follow-up at four TAVI locations in the Netherlands. Eligibility was initially assessed, and only patients with severe aortic stenosis and no contraindications for upper- or lower-extremity secondary access were notified of the trial and invited to participate. For secondary access during TAVI, the participants were randomly assigned to either the upper- or lower-extremity method (femoral artery diagnostic access and femoral vein for temporary pacing lead implantation). The primary endpoint was clinically significant bleeding in the randomized secondary access. Secondary endpoints were any clinically significant bleeding, time to mobility, secondary access failure, length of hospitalization, and procedural time.